香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 GIANT BIOGENE HOLDING CO., LTD 巨 子 生 物 控 股 有 限 公 司 （於開曼群島註冊成立的獲豁免有限公司） 2367 （股份代號： ） 2023 6 30 截 至 年 月 日 止 六 個 月 的 中 期 業 績 公 告 財務摘要 6 30 截至 月 日止六個月 2023 2022 年 年 變動 人民幣百萬元人民幣百萬元 1,605.7 984.9 63.0% 收入 1,351.0 838.3 61.2% 毛利 775.6 513.1 51.2% 稅前利潤 666.0 437.2 52.3% 淨利潤 歸屬於母公司持有者 666.9 437.2 52.5% 盈利 ...

Financial Performance - Total revenue for 2022 reached RMB 2,364.4 million, representing a 52.3% increase from RMB 1,552.5 million in 2021[9] - Gross profit for 2022 was RMB 1,995.2 million, up 47.3% from RMB 1,354.3 million in the previous year[9] - Profit before tax increased to RMB 1,177.7 million, a 21.1% rise compared to RMB 972.9 million in 2021[9] - Net profit for the year was RMB 1,001.6 million, reflecting a 21.0% growth from RMB 828.1 million in 2021[9] - Earnings attributable to equity holders of the parent amounted to RMB 1,002.0 million, a 21.0% increase from RMB 828.1 million in the prior year[9] - Adjusted net profit (non-IFRS measure) was RMB 1,056.4 million, up 24.1% from RMB 851.3 million in 2021[9] - Basic earnings per share for 2022 were RMB 0.99, compared to RMB 0.83 in 2021, marking a 19.3% increase[9] - Total assets as of December 31, 2022, were RMB 3,138.2 million, compared to RMB 2,651.1 million in 2021[11] - Total liabilities stood at RMB 301.2 million, a significant decrease from RMB 6,861.4 million in 2021[11] - Total equity reached RMB 2,837.0 million, up from RMB 1,016.8 million in the previous year[11] Revenue Breakdown - Revenue from professional skincare products reached RMB 1,561.6 million, accounting for 66.0% of total revenue, up from RMB 861.1 million (55.5%) in 2021[34] - Revenue from medical dressings was RMB 760.1 million, representing 32.2% of total revenue, compared to RMB 642.0 million (41.3%) in 2021[34] - The company's direct sales channel generated revenue of RMB 1,401.8 million, accounting for 59.3% of total revenue, while the distributor channel contributed RMB 962.6 million, making up 40.7%[26] - Sales revenue for the professional skincare product "可復美" reached RMB 1,613.0 million, an increase of 79.7% compared to 2021, accounting for 68.2% of total revenue in 2022[45] - "可麗金" generated sales revenue of RMB 618.4 million, up 17.6% from 2021, representing 26.2% of total revenue in 2022[46] - Other brands contributed RMB 90.3 million in sales revenue, a 13.8% increase from 2021, making up 3.8% of total revenue in 2022[47] - Sales revenue from health food and other products was RMB 42.7 million, a decrease of 13.7% from 2021, accounting for 1.8% of total revenue in 2022[48] Research and Development - Research and development (R&D) expenses increased by 76.5% year-on-year, totaling RMB 440 million, with an R&D expense ratio of 1.9%[18] - The company has applied for and authorized 80 patents, with 27 new patents added in 2022[18] - The company is involved in 4 national key research projects and 2 national high-tech research and development plans[18] - The company plans to enhance R&D investment in synthetic biology and develop new recombinant collagen and other bioactive ingredients[1] Sales and Marketing Strategy - The company has expanded its sales channels to over 1,300 public hospitals, approximately 2,000 private hospitals and clinics, and around 500 chain pharmacy brands in China[13] - The company has established a dual-track sales strategy targeting both medical institutions and the general consumer market, ensuring effective user engagement[27] - The company’s direct-to-consumer (DTC) sales primarily occur through e-commerce platforms, including Tmall, JD.com, Douyin, Xiaohongshu, and Pinduoduo[27] - The company emphasizes sustainable production practices, utilizing synthetic biology methods to reduce environmental impact and resource consumption[27] Corporate Governance - The company has a strong governance structure with members on the audit, nomination, and corporate governance committees[101] - The board consists of four executive directors and three independent non-executive directors, meeting the requirement of having at least one-third of the board as independent[109] - The company has established an audit committee consisting of independent non-executive directors to oversee financial reporting and risk management[121] - The company has implemented a corporate governance policy and practices, which are regularly reviewed and updated[126] Employee and Shareholder Relations - The company employed 933 full-time employees as of December 31, 2022, primarily located in Shaanxi Province, China[76] - The company has implemented a comprehensive training program for new hires and internal transfers to ensure employee competency[77] - The company provides competitive compensation and performance cash bonuses as part of its HR strategy to retain talent[77] - The company emphasizes effective communication with shareholders to enhance investor relations and transparency[149] Environmental, Social, and Governance (ESG) - The company’s first Environmental, Social, and Governance (ESG) report highlights its management practices and performance in economic, environmental, social, and governance aspects[156] - The report is prepared in accordance with the Hong Kong Stock Exchange's guidelines, ensuring the completeness, substance, authenticity, and balance of the information disclosed[157] - The company has established ESG performance indicators covering waste emissions, greenhouse gas emissions, energy usage, and quality safety[167] - The company has not reported any incidents of corruption or bribery during the reporting period[175] Risk Management - The company has established a risk management and internal control system to address identified risks, which includes regular assessments and updates[139] - The company plans to provide ongoing training for directors and senior management regarding relevant Chinese laws and regulations to proactively identify compliance issues[140] - The company has a governance committee that reviews corporate governance and ESG policies[136] Quality Management - The company has established a comprehensive quality management system, ensuring product quality safety throughout the entire lifecycle, compliant with various international standards[186] - The company has implemented a three-line defense mechanism for risk management, involving all departments, internal audit, and the board of directors[183] - The quality department conducts inspections on intermediates, semi-finished products, and finished products, ensuring that non-conforming products are not released[198]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 GIANT BIOGENE HOLDING CO., LTD 巨 子 生 物 控 股 有 限 公 司 （於開曼群島註冊成立的獲豁免有限公司） 2367 （股份代號： ） 2022 12 31 截 至 年 月 日 止 年 度 業 績 公 告 財務摘要 12 31 截至 月 日止年度 2022 年 2021年 變動 人民幣百萬元人民幣百萬元 收入 2,364.4 1,552.5 52.3% 毛利 1,995.2 1,354.3 47.3% 稅前利潤 1,177.7 972.9 21.1% 淨利潤 1,001.6 828.1 21.0% 歸屬於母公司持有者 盈利 1,002.0 828.1 21.0% 年內經調整淨利潤 （非《國際財務報告準則》 衡量指標） 1,056.4 851.3 24.1% ...